Skip to main content
. Author manuscript; available in PMC: 2020 Jun 17.
Published in final edited form as: Angew Chem Int Ed Engl. 2019 May 14;58(25):8479–8483. doi: 10.1002/anie.201903256

Figure 2. DOX@AuNPs enhanced anti-tumor efficacy of DOX among primary and metastatic tumor models.

Figure 2.

a–d) Normalized tumor growth curves and survival rates of the MCF-7 tumor-bearing nude mice (a, b) and 4T1 tumor-bearing balb/c mice (c, d) during successive treatments. For a and c, ****P<0.0001 (Student’s t-test). For b, * indicates <0.005, <0.0005 for DOX@AuNPs versus free DOX and PBS, respectively; For d, ** indicates P <0.001, <0.0005 for DOX@AuNPs versus free DOX and PBS, respectively (Kaplan-Meier, n = 6 – 8). To be noted, the AuNPs without DOX loading showed no tumor inhibition (Fig. S6). e) Images of mice lungs after the successive treatments (day-23). Scale bar, 1 mm. f) Nodule counts of the metastatic lung tumors after treatments. ***P<0.005 (n = 5). Box indicates median and s.e.m. g) Lung tumor nodule sizes. ****P<0.0001. Box indicates median and 25–75% interquartile range (Student’s t-test).